

WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Thursday, March 29, 2007

Hide?	Set Name	Query	Hit Count
	<i>DB=PGPB,USPT,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L11	L10 and monophasic	7
<input type="checkbox"/>	L10	L9 and insulin	1005
<input type="checkbox"/>	L9	L8 and diameter	1501
<input type="checkbox"/>	L8	L6 and (polyhydroxy\$ or polylact\$ or polyglycol\$)	2442
<input type="checkbox"/>	L7	L6	3711
<input type="checkbox"/>	L6	L5 and (polyethylene glycol)	3711
<input type="checkbox"/>	L5	L4 AND (alpha or beta or gamma)	4186
<input type="checkbox"/>	L4	L3 AND (MICROPART\$ OR NANOPART\$)	4215
<input type="checkbox"/>	L3	L2 AND (BIODEGRADABLE POLYMER)	14267
<input type="checkbox"/>	L2	L1 AND (HYDROPHILIC POLYMER)	15058
<input type="checkbox"/>	L1	(conjugate and interferon)	19095

END OF SEARCH HISTORY

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

End of Result Set

☐ [Generate Collection](#) [Print](#)

L11: Entry 7 of 7

File: USPT

Mar 16, 2004

US-PAT-NO: 6706289

DOCUMENT-IDENTIFIER: US 6706289 B2

TITLE: Methods and compositions for enhanced delivery of bioactive molecules

DATE-ISSUED: March 16, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lewis; Danny	Hartselle	AL		
Schmidt; Paul	Niwot	CO		
Hinds; Kenneth	Fort Collins	CO		

US-CL-CURRENT: [424/501](#); [424/423](#), [424/489](#), [424/502](#), [514/772.3](#)

CLAIMS:

What is claimed is:

1. A pharmaceutical formulation for controlled release of a bioactive molecule, the formulation comprising a biodegradable polymer in combination with a conjugate of a bioactive molecule and a hydrophilic polymer, wherein the formulation is in the form of microparticles or nanoparticles encapsulating the conjugate, the formulation having a lower initial burst than a formulation of the bioactive molecule without being conjugated to the hydrophilic polymer.
2. The pharmaceutical formulation of claim 1 wherein the bioactive molecule and the hydrophilic polymer are covalently conjugated.
3. The pharmaceutical formulation of claim 1 wherein the biodegradable polymer is selected from the group consisting of polyhydroxy acids, polylactic acids, polyglycolic acids, and copolymers thereof.
4. The pharmaceutical formulation of claim 3 wherein the biodegradable polymer is selected from the group consisting of polyanhydrides, polyorthoesters, and polysaccharide polymers.
5. The pharmaceutical formulation of claim 1 wherein the hydrophilic polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, copolymers of polyethylene glycol and polypropylene glycol, and linear and branched derivatives of polyethylene glycol and polyethylene glycol/polypropylene glycol copolymers.
6. The pharmaceutical formulation of claim 1 wherein said bioactive molecule is selected from the group consisting of .alpha.-interferon, .beta.-

*Terminal Disclaimer
Filed ✓*

interferon, .gamma.-interferon, erythropoietins, granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, interleukin 1, interleukin 2, interleukin 3, interleukin 12, asparaginase, adenosine deaminase, insulin, glucagon-like peptides, ACTH, glucagon, somatostatin, somatostatin, rhymosin, parathyroid hormone, pigmentary hormones, somatomedin, leuteinizing hormone, chorionic gonadotropin, hypothalamic releasing factors, antidiuretic hormones, thyroid stimulating hormone, endorphins, enkephalins, biphalin, prolactin, monoclonal antibodies, polyclonal antibodies, antisense oligonucleotides, aptamers, therapeutic genes, heparin, low molecular weight heparin and small bioactive molecules.

7. A method for controlled systemic delivery of bioactive molecules to a subject comprising administering to the subject a formulation comprising a biodegradable polymer in combination with a conjugate of a bioactive molecule and a hydrophilic polymer, wherein the formulation is in the form of microparticles or nanoparticles encapsulating the conjugate, the formulation having a lower initial burst than a formulation of the bioactive molecule without being conjugated to the hydrophilic polymer.

8. The method of claim 7 wherein the composition is administered orally.

9. The method of claim 7 wherein the composition is administered by inhalation or mucosal delivery.

10. The method of claim 7 wherein the composition is administered by injection.

11. The method of claim 10 wherein the injection is subcutaneous or intramuscular.

12. The method of claim 7 wherein the bioactive molecule and the hydrophilic polymer are covalently conjugated.

13. The method of claim 7 wherein the biodegradable polymer is selected from the group consisting of polyhydroxy acids, polylactic acids, polyglycolic acids, and copolymers thereof.

14. The method of claim 7, wherein the hydrophilic polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, copolymers of polyethylene glycol and polypropylene glycol, and linear and branched derivatives of polyethylene glycol and polyethylene glycol/polypropylene glycol copolymers.

15. The method of claim 7 wherein said bioactive molecule is selected from the group consisting of .alpha.-interferon, .beta.-interferon, .gamma.-interferon, erythropoietins, granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, interleukin 1, interleukin 2, interleukin 3, interleukin 12, asparaginase, adenosine deaminase, insulin, glucagon-like peptides, ACTH, glucagon, somatostatin, somatotropin, thymosin, parathyroid hormone, pigmentary hormones, somatomedin, leuteinizing hormone, chorionic gonadotropin, hypothalamic releasing factors, antidiuretic hormones, thyroid stimulating hormone, endorphins, enkephalins, biphalin, prolactin, monoclonal antibodies, polyclonal antibodies, antisense oligonucleotides, aptamers, therapeutic genes, heparin, low molecular weight heparin and small bioactive molecules.

16. A method for increasing bioavailability of a bioactive molecule,

comprising conjugating the bioactive molecule with a hydrophilic polymer, formulating the conjugated bioactive molecule with a biodegradable polymer, wherein the biodegradable polymer is in the form of microparticles or nanoparticles encapsulating the conjugated bioactive molecule, and administering the resulting formulation to a subject, the formulation having a lower initial burst than a formulation of the bioactive molecule without being conjugated to the hydrophilic polymer.

17. The method of claim 16 wherein the formulation is administered orally.

18. The method of claim 16 wherein the bioactive molecule and the hydrophilic polymer are covalently conjugated.

19. The method of claim 16 wherein the biodegradable polymer is selected from the group consisting of polyhydroxy acids, polylactic acids, polyglycolic acids, and copolymers thereof.

20. The method of claim 16 wherein the hydrophilic polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, copolymers of polyethylene glycol and polypropylene glycol, and linear and branched derivatives of polyethylene glycol and polyethylene glycol/polypropylene glycol copolymers.

21. The method of claim 16, wherein said bioactive molecule is selected from the group consisting of .alpha.-interferon, .beta.-interferon, .gamma.-interferon, erythropoietins, granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, interleukin 1, interleukin 2, interleukin 3, interleukin 12, asparaginase, adenosine deaminase, insulin, glucagon-like peptides, ACTH, glucagon, somatostatin, somatotropin, thymosin, parathyroid hormone, pigmentary hormones, somatomedin, leuteinizing hormone, chorionic gonadotropin, hypothalamic releasing factors, antidiuretic hormones, thyroid stimulating hormone, endorphins, enkephalins, biphalin, prolactin, monoclonal antibodies, polyclonal antibodies, antisense oligonucleotides, aptamers, therapeutic genes, heparin, low molecular weight heparin and small bioactive molecules.

22. A method for reducing immunogenicity of a bioactive molecule, comprising conjugating the bioactive molecule with a hydrophilic polymer, formulating the conjugated bioactive molecule with a biodegradable polymer, and administering the resulting formulation to a subject, wherein the formulation is in the form of microparticles or nanoparticles encapsulating the conjugate, the formulation having a lower initial burst than a formulation of the bioactive molecule without being conjugated to the hydrophilic polymer.

23. The method of claim 22 wherein the formulation is administered orally.

24. The method of claim 22 wherein the bioactive molecule and the hydrophilic polymer are covalently conjugated.

25. The method of claim 22 wherein the biodegradable polymer is selected from the group consisting of polyhydroxy acids, polylactic acids, polyglycolic acids, and copolymers thereof.

26. The method of claim 22 wherein the hydrophilic polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, copolymers of polyethylene glycol and polypropylene glycol, and linear and branched derivatives of polyethylene glycol or polyethylene glycol/polypropylene glycol

copolymers.

27. The method of claim 22, wherein said bioactive molecule is selected from the group consisting of .alpha.-interferon, .beta.-interferon, .gamma.-interferon, erythropoietins, granulocyte colony stimulating factor, interleukin 1, interleukin 2, interleukin 3, interleukin, 12, asparaginase, adenosine deaminase, insulin, glucagon-like peptides, ACTH, glucagon, somatostatin, somatotropin, thymosin, parathyroid hormone, pigmentary hormones, somatomedin, leuteinizing hormone, chorionic gonadotropin, hypothalamic releasing factors, antidiuretic hormones, thyroid stimulating hormone, endorphins, enkephalins, biphalin, prolactin, monoclonal antibodies, polyclonal antibodies, antisense oligonucleotides, aptamers, therapeutic genes, heparin, low molecular weight heparin and small bioactive molecules.

28. A method for producing a pharmaceutical formulation for controlled release of a bioactive molecule, the method comprising: dissolving (a) a biodegradable polymer and (b) a conjugate of a bioactive molecule and a hydrophilic polymer in a solvent to form a monophase, and forming microparticles or nanoparticles comprising the biodegradable polymer encapsulating the conjugate.

29. The formulation of claim 1, wherein the biodegradable polymer comprises a copolymer of polylactic acid and polyglycolic acid and the hydrophilic polymer comprises polyethylene glycol.

30. The formulation of claim 1, wherein the bioactive molecule is selected from the group consisting of a protein, a peptide and a small molecule.

31. The formulation of claim 1, wherein the bioactive molecule comprises insulin.

32. A pharmaceutical formulation for controlled release of a bioactive molecule, the formulation comprising a biodegradable polymer in combination with a conjugate of a bioactive molecule and a hydrophilic polymer, wherein the biodegradable polymer comprises a derivatized biodegradable polymer containing hydrophilic and hydrophobic regions.

33. The formulation of claim 32, wherein the hydrophilic region comprises polyethylene glycol.

34. The formulation of claim 32, wherein the bioactive molecule comprises insulin.

35. The formulation of claim 32, wherein the hydrophobic region comprises a polymer selected from the group consisting of polyhydroxy acids, polylactic acids, polyglycolic acids, and copolymers thereof.

36. The formulation of claim 1, wherein the hydrophilic polymer comprises polyethylene glycol.

37. A pharmaceutical formulation for controlled release of a bioactive molecule, the formulation comprising a biodegradable polymer in combination with a conjugate of a bioactive molecule and a hydrophilic polymer, wherein the conjugate of the hydrophilic polymer and a bioactive agent is predominantly a single species.

38. The formulation of claim 37, wherein the hydrophilic polymer comprises

polyethylene glycol.

39. The formulation of claim 38, wherein the polyethylene glycol is linked to the bioactive molecule predominantly at a single site on the bioactive molecule.

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)